A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biological meningococcal conjugate vaccine, MenACWYTT (GSK134612) in healthy infants, given on a 3+1 primary and booster (2, 4, 6 and 15-18 months of age), a 1+1 primary and booster (6 and 15-18 months of age), or as a single dose at 15-18 months of age

drug protocol number
114858
drug sponsor
GSK
drug study
Infanrix-IPV/HiberixTM/SynflorixTM/GSK 134612
drug trial site
N\A
drug status
Rejected
drug phase